PedAM
Pediatric Disease Annotations & Medicines
| typhoid fever | ||||
| Disease ID | 527 |
|---|---|
| Disease | typhoid fever |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:18) HP:0012115 | Liver inflammation | 4 HP:0001945 | Fever | 2 HP:0001744 | Splenomegaly | 1 HP:0001662 | Bradycardia | 1 HP:0003249 | Genital ulcers | 1 HP:0002586 | Peritonitis | 1 HP:0012819 | Myocarditis | 1 HP:0001935 | Microcytic anemia | 1 HP:0002239 | Gastrointestinal hemorrhage | 1 HP:0002027 | Abdominal pain | 1 HP:0002584 | Intestinal hemorrhage | 1 HP:0000709 | Psychosis | 1 HP:0002099 | Asthma | 1 HP:0001903 | Anemia | 1 HP:0001082 | Cholecystitis | 1 HP:0002014 | Diarrhea | 1 HP:0006824 | Cranial nerve palsy | 1 HP:0002240 | Enlarged liver | 1 |
| Disease ID | 527 |
|---|---|
| Disease | typhoid fever |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:10) C0009450 | infection | 6 C0021845 | intestinal perforation | 2 C0033975 | psychosis | 1 C0011991 | diarrhea | 1 C0027059 | myocarditis | 1 C0267373 | intestinal bleeding | 1 C0031154 | peritonitis | 1 C0002871 | anemia | 1 C0272412 | splenic abscess | 1 C1328486 | calculous cholecystitis | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1800610 | 17503085 | 7124 | TNF | umls:C0041466 | GAD | [A TNF region haplotype offers protection from typhoid fever in Vietnamese patients.] | 0.008544182 | 2007 | TNF | 6 | 31576050 | G | A |
| rs4646205 | 20233062 | 1080 | CFTR | umls:C0041466 | GAD | [Distribution of CFTR variations in an Indonesian enteric fever cohort.] | 0.005276948 | 2010 | CFTR | 7 | 117548607 | TG | - |
| rs4986790 | 21612766 | 7099 | TLR4 | umls:C0041466 | BeFree | Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and typhoid susceptibility in Asian Malay population in Malaysia. | 0.003181358 | 2011 | TLR4 | 9 | 117713024 | A | G |
| rs4986791 | 21612766 | 7099 | TLR4 | umls:C0041466 | BeFree | Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and typhoid susceptibility in Asian Malay population in Malaysia. | 0.003181358 | 2011 | TLR4 | 9 | 117713324 | C | T |
| rs7765379 | 25383971 | 3133 | HLA-E | umls:C0041466 | BeFree | Imputation-based fine-mapping across the extended MHC region showed that the classical HLA-DRB1*04:05 allele (OR = 0.14, P = 2.60 × 10(-11)) could entirely explain the association at rs7765379, thus implicating HLA-DRB1 as a major contributor to resistance against enteric fever, presumably through antigen presentation. | 0.000542884 | 2014 | NA | 6 | 32713151 | T | G |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0041466 | chloramphenicol | D002701 | 56-75-7 | typhoid fever | MESH:D014435 | therapeutic | 3289662 | ||
| C0041466 | ciprofloxacin | D002939 | 85721-33-1 | typhoid fever | MESH:D014435 | therapeutic | 8427378 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D014435 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D014435 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D014435 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D014435 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |